New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:07 EDTCLSNCelsion announces FDA clearance of the OPTIMA study
Celsion announced that the FDA has reviewed and provided clearance for the company's planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation in primary liver cancer, also known as hepatocellular carcinoma. The trial design is based on a comprehensive analysis of data from the Company's Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment. Celsion expects to launch the study in the first half of 2014.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
09:36 EDTCLSNActive equity options trading
Subscribe for More Information
October 30, 2014
10:02 EDTCLSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTCLSNCelsion initiated with a Buy at Cantor
Subscribe for More Information
October 29, 2014
08:18 EDTCLSNCelsion presents positive data for its Therasilence platform
Celsion presented data related to TheraSilence, its lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2, Celsion's RNA interference therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June. Intravenous delivery of RNA inhibiting VEGFR-2, a tumor angiogenesis factor, with the TheraSilence delivery system resulted in significant knockdown of VEGFR-2 transcript in lungs, reduction in tumor blood vessel density and inhibition of tumor growth. Systemically administered RNA complexes using the TheraSilence delivery system demonstrated a good tolerability profile.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use